Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus

Drugs and Aging

Volumn 18, Issue 5, 2001, Pages 325-333

  Wilson, Stephanie H ^a   Kennedy, Frank P ^a   Garratt, Kirk N ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MEGLITINIDE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ACUTE HEART INFARCTION; AGED; ATHEROSCLEROSIS; BLOOD CLOT LYSIS; DISEASE COURSE; DRUG MECHANISM; DYSLIPIDEMIA; EXERCISE; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; SMOKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0035015622     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200118050-00003     Document Type: Review

References (54)

1. 1. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18 (2): 258-68
2. 2. Klein R, Klein BE, Moss SE. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124 (1 Pt 2): 90-6
3. 3. Anonymous. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-53
4. 4. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995; 18 (8): 1113-23
5. 5. Anonymous. The University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 1975; 24 Suppl. 1: 65-184
6. 6. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314 (7093): 1512-5
7. 7. Helmrich SP, Ragland DR, Leung RW, et al. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med 1991; 325 (3): 147-52
8. 8. Holman RR, Cull CA, Turner RC, et al. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4
9. 9. Brady PA, Alekseev AE, Aleksandrova LA, et al. A disrupter of actin microfilaments impairs sulfonylurea-inhibitory gating of cardiac KATP channels. Am J Physiol 1996; 271 (6 Pt 2): H2710-6
10. 10. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 1998; 31(5): 950-6
11. 11. Edwards G, Weston AH. The pharmacology of ATP-sensitive potassium channels. Annu Rev Pharmacol Toxicol 1993; 33: 597-637
12. 12. Ashcroft SJ, Ashcroft FM. The sulfonylurea receptor. Biochimica Biophysica Acta 1992; 1175 (1): 45-59
13. 13. Terzic A, Jahangir A, Kurachi Y. Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs. Am J Physiol 1995; 269 (3 Pt 1): C525-45
14. 14. Findlay I. Effects of pH upon the inhibition by sulphonylurea drugs of ATP-sensitive K+ channels in cardiac muscle. J Pharmacol Exp Ther 1992; 262 (1): 71-9
15. 15. Tomai F, Crea F, Gaspardone A, et al. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation 1994; 90 (2): 700-5
16. 16. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33 (1): 119-24
17. 17. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1998 Nov 7; 352 (9139): 1557]. Lancet 1998; 352 (9131): 854-65
18. 18. Fonseca VA, Valiquett TR, Huang SM, et al. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group. J Clin Endocrinol Metab 1998; 83 (9): 3169-76
19. 19. Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation: a case report Ann Intern Med 1998; 129: 38-41
20. 20. Marbury TC, Ruckle JL, Hatorp V, et al. Clin Pharmacol Ther 2000; 67: 7-15
21. 21. Lichtenstein MJ, Yarnell JW, Elwood PC, et al. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol 1987; 126 (4): 647-57
22. 22. Logan RL, Riemersma RA, Thomson M, et al. et al. Risk factors for ischaemic heart-disease in normal men aged 40. Edinburgh-Stockholm Study. Lancet 1978; 1 (8071): 949-54
23. 23. Fontbonne A, Tchobroutsky G, Eschwege E, et al. Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obesity 1988; 12 (6): 557-65
24. 24. Stout RW, Bierman EL, Ross R. Effect of insulin on the proliferation of cultured primate arterial smooth muscle cells. Circulation Res 1975; 36 (2): 319-27
25. 25. Motani A, Forster L, Tull S, et al. Insulin-like growth factor-I modulates monocyte adhesion to EAhy 926 endothelial cells. Int J Exp Pathol 1996; 77 (1): 31-5
26. 26. Boyne MS, Saudek CD. Effect of insulin therapy on macrovascular risk factors in type 2 diabetes. Diabetes Care 1999; 22 Suppl. 3: C45-53
27. 27. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158 (2): 134-40
28. 28. Haffner SM. Diabetes, hyperlipidemia, and coronary artery disease. Am J Cardiol 1999; 83 (9B): 30-5F
29. 29. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) [published erratum appears in Diabetes Care 1997 Jun; 20 (6): 1048]. Diabetes Care 1997; 20 (4): 614-20
30. 30. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. The Care Investigators. Circulation 1998; 98 (23): 2513-9
31. 31. Koskinen P, Mänttäri M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-25
32. 32. Bilo HJ, Gans RO. Hypertensive patients and diabetes: a high-risk population. J Cardiovasc Pharmacol 1998; 32 Suppl. 2: S1-8
33. 33. Anonymous. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group [published erratum appears in BMJ 1999 Jan 2; 318 (7175): 29]. BMJ 1998; 317 (7160): 703-13
34. 34. Carney AJ, Carney TA. Use of aspirin in secondary prevention of coronary heart disease is rising [letter]. BMJ 1996; 312: 846
35. 35. Yusuf S, Lessen J, Jha P, et al. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens Suppl 1993; 11: S61-73
36. 36. Anonymous. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992; 268 (10): 1292-300
37. 37. Colwell JA. Aspirin therapy in diabetes. Diabetes Care 1997; 20 (11): 1767-71
38. 38. Jonas M, Reicher-Reiss H, Boyko V, et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77 (15): 1273-7
39. 39. Cashin-Hemphill L, Holmvang G, Chan RC, et al. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am J Cardiol 1999; 83 (1): 43-7
40. 40. Anonymous. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355 (9200): 253-9
41. 41. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes 1992; 41 Suppl. 2: 26-31
42. 42. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94 (8): 1818-25
43. 43. Serruys PW, de Jaegere P. Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331 (8): 489-95
44. 44. Abizaid A, Kornowski R, Mintz GS, et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Coll Cardiol 1998; 32 (3): 584-9
45. 45. Van Belle E, Bauters C, Hubert E, et al. Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96 (5): 1454-60
46. 46. Anonymous. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [published erratum appears in N Engl J Med 1997 Jan 9; 336 (2): 147]. N Engl J Med 1996; 335 (4): 217-25
47. 47. Ferguson JJ. NHLI BARI clinical alert on diabetics treated with angioplasty [news]. Circulation 1995; 92 (12): 3371
48. 48. Detre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99 (5): 633-40
49. 49. Weintraub WS, Mauldin PD, Becker E, et al. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 1995; 92 (10): 2831-40
50. 50. Barsness GW, Peterson ED, Ohman EM, et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997; 96 (8): 2551-6
51. 51. Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341 (5): 319-27
52. 52. Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30 (1): 171-9
53. 53. Pfeffer MA, Moye LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. JAMA 1991; 266 (4): 528-32
54. 54. Stone GW, Grines CL, Browne KF, et al. Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Catheterization Cardiovasc Diagn 1996; 39 (4): 333-9\